FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a stable pharmaceutical composition for treating cancer containing a water-soluble salt of vinflunine ditartrate and at least one diluent, one binding substance, one aerating agent and one lubricating agent wherein the composition is presented in a solid form for oral application wherein: the content of the water-soluble salt of vinflunine ditartrate makes 5 to 80 wt %, the content of the diluent makes 20 to 80 wt % of total weight of the composition, the content of the binding substance makes 1 to 10 wt % of total weight of the composition, the content of the lubricating agent makes 0.5 to 10 wt % of total weight of the composition, the content of the aerating agent makes 1 to 10 wt % of total weight of the composition.
EFFECT: invention provides storage stability at 5°C for 24 months in a sealed package.
19 cl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE PHARMACEUTICAL COMPOSITION OF WATER-SOLUBLE SALT OF VINORELBINE | 2008 |
|
RU2476208C2 |
| IMPROVED PHARMACEUTICAL PREPARATIONS CONTAINING IBUPROFEN AND CODEINE | 1995 |
|
RU2140782C1 |
| TABLET CONTAINING FLUVASTATIN AND SODIUM CARBOXYMETHYLCELLULOSE OF CALCIUM | 2004 |
|
RU2361582C2 |
| HALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2005 |
|
RU2384328C2 |
| ESCITALOPRAM AND HARD PHARMACETICAL COMPOSITION CONTAINING IT | 2007 |
|
RU2463039C2 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2009 |
|
RU2438661C2 |
| PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN LOBEGLITAZONE FOR ORAL ADMINISTRATION | 2015 |
|
RU2709526C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES | 2010 |
|
RU2533560C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ALEGLITEZAR | 2010 |
|
RU2537224C2 |
| ORAL SOLID DOSAGE FORM AND METHOD OF TREATING | 2011 |
|
RU2480210C1 |
